27 June 2022
Children who are diagnosed with type 1 diabetes in early childhood have the most rapid loss of beta cells, research shows.
20 June 2022
The risk of relapse after treatment for childhood acute lymphoblastic leukaemia (ALL) has decreased in the past 3 decades but the likelihood of successful treatment of relapse has not improved, suggests a review of three Nordic Society of Pediatric Hematology and Oncology (NOPHO) clinical trials.
16 June 2022
Paris, France, Boston, United States, 7 June 2022 – L’Institut Servier, Gustave Roussy (Villejuif, France), and Dana-Farber Cancer Institute (Boston, USA) have signed a cooperation agreement to foster exchange and develop bilateral collaboration among researchers from these two renowned oncology centers.
13 June 2022
People with systemic lupus erythematosus (SLE) are more likely to have autoantibodies against post-translationally modified (PTM) proteins than healthy controls, and these antibodies are associated with neuropsychiatric manifestations, researchers report in RMD Open.
8 June 2022
Children diagnosed with attention deficit/hyperactivity disorder (ADHD) before puberty have evidence of changes in their gut microbiota before the age of 1 year, research shows.
30 May 2022
Screening for mitogen-activated protein kinase (MAPK) signalling pathway alterations in children and young adults with cancer or histiocytic disorders is feasible, but targeted therapy with selumetinib showed “limited efficacy” in this population, say the NCI-COG Pediatric MATCH trial investigators.
13 May 2022
A night-time only infusion of the dopamine agonist apomorphine could help to reduce sleep disturbances in patients with advanced Parkinson’s disease and moderate-to-severe insomnia, suggest the results of the APOMORPHEE trial.
9 May 2022
Study findings suggest that higher blood neutrophil counts and neutrophil-to-lymphocyte ratio (NLR) are associated with an increased risk for disease progression and mortality in patients with early systemic sclerosis (SSc).
3 May 2022
Researchers have identified an association between faster rates of increase of TREM2 levels in soluble cerebrospinal fluid (CSF) and slower progression of several markers of disease evolution in participants of the Dominantly Inherited Alzheimer Network (DIAN), which they say points to a likely protective effect of TREM2 during the early pathogenesis of Alzheimer’s disease.
25 April 2022
Autoantibodies against interleukin-1 receptor antagonist (IL-1Ra) are present in a large proportion of patients with multisystem inflammatory syndrome in children (MIS-C), say researchers.